Human engineered heart tissue as a model system for drug testing

Advanced Drug Delivery Reviews

Volumn 96, Issue , 2016, Pages 214-224

  Eder, Alexandra ^a,b   Vollert, Ingra ^a,b   Hansen, Arne ^a,b   Eschenhagen, Thomas ^a,b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

Cardiac safety pharmacology; Drug development; Engineered heart tissue; Human induced pluripotent stem cell derived cardiomyocytes; Maturation; Screening assays

Indexed keywords

DRUG INTERACTIONS; GENE EXPRESSION; HEART; SILICONES; STEM CELLS; TISSUE;

CARDIOMYOCYTES; DRUG DEVELOPMENT; ENGINEERED HEART TISSUES; MATURATION; SAFETY PHARMACOLOGY; SCREENING ASSAYS;

DRUG PRODUCTS;

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; ALFUZOSIN; AMINOPYRIDINE; AMLODIPINE; CAFFEINE; CARBACHOL; CHROMANOL 293B; CISAPRIDE; DILTIAZEM; DOFETILIDE; ERYTHROMYCIN; FAMPRIDINE; ISOPRENALINE; LIDOCAINE; MIBEFRADIL; NIFEDIPINE; NORADRENALIN; PHENYTOIN; PROCAINAMIDE; QUINIDINE; SOTALOL; TERFENADINE; VERAPAMIL; ZATEBRADINE;

CELL MATURATION; CELL METABOLISM; CELL SIZE; CELL STRUCTURE; DISEASE MODEL; DRUG DEVELOPMENT; DRUG MECHANISM; DRUG SCREENING; ENGINEERED HEART TISSUE; EUROPEAN MEDICINES AGENCY; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; HEART; HEART CELL CULTURE; HEART MUSCLE CELL; HEART REPOLARIZATION; HEART STIMULATION; HEART VENTRICLE HYPERTROPHY; HIGH THROUGHPUT SCREENING; HUMAN; HYDROGEL; HYPERTROPHIC CARDIOMYOPATHY; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; RELAXATION TIME; REVIEW; TISSUE ENGINEERING; VIDEORECORDING; ACTION POTENTIAL; ANIMAL; CARDIAC MUSCLE CELL; CYTOLOGY; DRUG EFFECTS; HEART CONTRACTION; INDUCED PLURIPOTENT STEM CELL; PHYSIOLOGY; PRECLINICAL STUDY; PROCEDURES; SPECIES DIFFERENCE;

ACTION POTENTIALS; ANIMALS; DRUG EVALUATION, PRECLINICAL; HEART; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; SPECIES SPECIFICITY; TISSUE ENGINEERING;

EID: 84951736187     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.05.010     Document Type: Review

References (105)

1. Bowes J., Brown A.J., Hamon J., Jarolimek W., Sridhar A., Waldron G., et al. Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nat. Rev. Drug Discov. 2012, 11:909-922. 10.1038/nrd3845.
2. Laverty H., Benson C., Cartwright E., Cross M., Garland C., Hammond T., et al. How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?. Br. J. Pharmacol. 2011, 163:675-693. 10.1111/j.1476-5381.2011.01255.
3. Olson H., Betton G., Robinson D., Thomas K., Monro A., Kolaja G., et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 2000, 32:56-67. 10.1006/rtph.2000.1399.
4. Sasseville V.G., Lane J.H., Kadambi V.J., Bouchard P., Lee F.W., Balani S.K., et al. Testing paradigm for prediction of development-limiting barriers and human drug toxicity. Chem. Biol. Interact. 2004, 150:9-25. 10.1016/j.cbi.2004.06.009.
5. FDA Guidance for Industry S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals 2005.
6. Peng S., Lacerda A.E., Kirsch G.E., Brown A.M., Bruening-Wright A. The action potential and comparative pharmacology of stem cell-derived human cardiomyocytes. J. Pharmacol. Toxicol. Methods 2010, 61:277-286. 10.1016/j.vascn.2010.01.014.
7. Martin R.L., McDermott J.S., Salmen H.J., Palmatier J., Cox B.F., Gintant G.A. The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block. J. Cardiovasc. Pharmacol. 2004, 43:369-379. 10.1097/00005344-200403000-00007.
8. Kehat I., Kenyagin-Karsenti D., Snir M., Segev H., Amit M., Gepstein A., et al. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J. Clin. Invest. 2001, 108:407-414. 10.1172/JCI12131.
9. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676. 10.1016/j.cell.2006.07.024.
10. Navarrete E.G., Liang P., Lan F., Sanchez-Freire V., Simmons C., Gong T., et al. Screening drug-induced arrhythmia events using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays. Circulation 2013, 128:S3-S13. 10.1161/CIRCULATIONAHA.112.000570.
11. Ivashchenko C.Y., Pipes G.C., Lozinskaya I.M., Lin Z., Xiaoping X., Needle S., et al. Human-induced pluripotent stem cell-derived cardiomyocytes exhibit temporal changes in phenotype. Am. J. Physiol. Heart Circ. Physiol. 2013, 305:H913-H922. 10.1152/ajpheart.00819.2012.
12. 2+ channel pharmacology between native and stem cell-derived cardiomyocytes. J. Pharmacol. Exp. Ther. 2012, 341:510-517. 10.1124/jpet.112.192609.
13. 2+ channels in human fetal ventricular myocytes. J. Cardiovasc. Electrophysiol. 1999, 10:692-700. 10.1111/j.1540-8167.1999.tb00246.
14. Mitcheson J.S., Chen J., Lin M., Culberson C., Sanguinetti M.C. A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:12329-12333. 10.1073/pnas.210244497.
15. Fernandez D., Ghanta A., Kauffman G.W., Sanguinetti M.C. Physicochemical features of the hERG channel drug binding site. J. Biol. Chem. 2004, 279:10120-10127. 10.1074/jbc.M310683200.
16. Del Rosario M.E., Weachter R., Flaker G.C. Drug-induced QT prolongation and sudden death. Mo. Med. 2010, 107:53-58.
17. Wakefield I.D., Pollard C., Redfern W.S., Hammond T.G., Valentin J.-P. The application of in vitro methods to safety pharmacology. Fundam. Clin. Pharmacol. 2002, 16:209-218. 10.1046/j.1472-8206.2002.00099.x.
18. Hoffmann P., Warner B. Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. J. Pharmacol. Toxicol. Methods 2006, 53:87-105. 10.1016/j.vascn.2005.07.003.
19. Heijman J., Voigt N., Carlsson L.G., Dobrev D. Cardiac safety assays. Curr. Opin. Pharmacol. 2014, 15:16-21. 10.1016/j.coph.2013.11.004.
20. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 2003, 58:32-45. 10.1016/S0008-6363(02)00846-5.
21. Meyer T., Sartipy P., Blind F., Leisgen C., Guenther E. New cell models and assays in cardiac safety profiling. Expert Opin. Drug Metab. Toxicol. 2007, 3:507-517. 10.1517/17425225.3.4.507.
22. Kannankeril P., Roden D.M., Darbar D. Drug-induced long QT syndrome. Pharmacol. Rev. 2010, 62:760-781. 10.1124/pr.110.003723.
23. Himmel H.M. Suitability of commonly used excipients for electrophysiological in-vitro safety pharmacology assessment of effects on hERG potassium current and on rabbit Purkinje fiber action potential. J. Pharmacol. Toxicol. Methods 2007, 56:145-158. 10.1016/j.vascn.2007.04.004.
24. Gelzer A.R., Ball H.A. Validation of a telemetry system for measurement of blood pressure, electrocardiogram and locomotor activity in beagle dogs. Clin. Exp. Hypertens. 1997, 19:1135-1160. 10.3109/10641969709083209.
25. Lamore S.D., Kamendi H.W., Scott C.W., Dragan Y.P., Peters M.F. Cellular impedance assays for predictive preclinical drug screening of kinase inhibitor cardiovascular toxicity. Toxicol. Sci. 2013, 135:402-413. 10.1093/toxsci/kft167.
26. Kramer J., Obejero-Paz C.A., Myatt G., Kuryshev Y.A., Bruening-Wright A., Verducci J.S., et al. MICE models: superior to the HERG model in predicting Torsade de Pointes. Sci. Rep. 2013, 3:2100. 10.1038/srep02100.
27. Tang H., Shen D.R., Han Y.-H., Kong Y., Balimane P., Marino A., et al. Development of novel, 384-well high-throughput assay panels for human drug transporters: drug interaction and safety assessment in support of discovery research. J. Biomol. Screen. 2013, 18:1072-1083. 10.1177/1087057113494807.
28. Ahuja V., Sharma S. Drug safety testing paradigm, current progress and future challenges: an overview. J. Appl. Toxicol. 2014, 34:576-594. 10.1002/jat.2935.
29. On G.O., Trout R., Tm F., Myeloid U., Sensitisation S., Finalised T., et al. ECVAM Test Method Submissions 2008-2014 2014, 1-10.
30. ECVAM (access: 2015-03-12). https://eurl-ecvam.jrc.ec.europa.eu/test-submission/tests-submitted-to-eurl-ecvam/tsar-table-updated-15-09-2014.
31. Yang X., Pabon L., Murry C.E. Engineering adolescence: maturation of human pluripotent stem cell-derived cardiomyocytes. Circ. Res. 2014, 114:511-523. 10.1161/CIRCRESAHA.114.300558.
32. Mewes T., Ravens U. L-type calcium currents of human myocytes from ventricle of non-failing and failing hearts and from atrium. J. Mol. Cell. Cardiol. 1994, 26:1307-1320.
33. Sheng X., Reppel M., Nguemo F., Mohammad F.I., Kuzmenkin A., Hescheler J., et al. Human pluripotent stem cell-derived cardiomyocytes: response to TTX and lidocaine reveals strong cell to cell variability. PLoS One 2012, 7:e45963. 10.1371/journal.pone.0045963.
34. Gerdes A.M., Kellerman S.E., Moore J.A., Muffly K.E., Clark L.C., Reaves P.Y., et al. Structural remodeling of cardiac myocytes in patients with ischemic cardiomyopathy. Circulation 1992, 86:426-430. 10.1161/01.CIR.86.2.426.
35. Lieu D.K., Liu J., Siu C.-W., McNerney G.P., Tse H.-F., Abu-Khalil A., et al. Absence of transverse tubules contributes to non-uniform Ca(2+) wavefronts in mouse and human embryonic stem cell-derived cardiomyocytes. Stem Cells Dev. 2009, 18:1493-1500. 10.1089/scd.2009.0052.
36. Gherghiceanu M., Barad L., Novak A., Reiter I., Itskovitz-Eldor J., Binah O., et al. Cardiomyocytes derived from human embryonic and induced pluripotent stem cells: comparative ultrastructure. J. Cell. Mol. Med. 2011, 15:2539-2551. 10.1111/j.1582-4934.2011.01417.
37. Ma J., Guo L., Fiene S.J., Anson B.D., Thomson J.A., Kamp T.J., et al. High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. AJP Hear. Circ. Physiol. 2011, 301:H2006-H2017. 10.1152/ajpheart.00694.2011.
38. van den Heuvel N.H.L., van Veen T.A.B., Lim B., Jonsson M.K.B. Lessons from the heart: mirroring electrophysiological characteristics during cardiac development to in vitro differentiation of stem cell derived cardiomyocytes. J. Mol. Cell. Cardiol. 2014, 67:12-25. 10.1016/j.yjmcc.2013.12.011.
39. Lundy S.D., Zhu W.-Z., Regnier M., Laflamme M.A. Structural and functional maturation of cardiomyocytes derived from human pluripotent stem cells. Stem Cells Dev. 2013, 22:1991-2002. 10.1089/scd.2012.0490.
40. Germanguz I., Sedan O., Zeevi-Levin N., Shtrichman R., Barak E., Ziskind A., et al. Molecular characterization and functional properties of cardiomyocytes derived from human inducible pluripotent stem cells. J. Cell. Mol. Med. 2011, 15:38-51. 10.1111/j.1582-4934.2009.00996.x.
41. Eschenhagen T., Fink C., Remmers U., Scholz H., Wattchow J., Weil J., et al. Three-dimensional reconstitution of embryonic cardiomyocytes in a collagen matrix: a new heart muscle model system. FASEB J. 1997, 11:683-694.
42. Zimmermann W.-H., Schneiderbanger K., Schubert P., Didié M., Münzel F., Heubach J.F., et al. Tissue engineering of a differentiated cardiac muscle construct. Circ. Res. 2002, 90:223-230. 10.1161/hh0202.103644.
43. Schaaf S., Shibamiya A., Mewe M., Eder A., Stöhr A., Hirt M.N., et al. Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology. PLoS One 2011, 6:e26397. 10.1371/journal.pone.0026397.
44. 2+ transients in engineered heart tissue. Am. J. Physiol. Heart Circ. Physiol. 2014, 306:H1353-H1363. 10.1152/ajpheart.00705.2013.
45. Fink C., Ergün S., Kralisch D., Remmers U., Weil J., Eschenhagen T. Chronic stretch of engineered heart tissue induces hypertrophy and functional improvement. FASEB J. 2000, 14:669-679.
46. Hansen A., Eder A., Bönstrup M., Flato M., Mewe M., Schaaf S., et al. Development of a drug screening platform based on engineered heart tissue. Circ. Res. 2010, 107:35-44. 10.1161/CIRCRESAHA.109.211458.
47. Eschenhagen T., Eder A., Vollert I., Hansen A. Physiological aspects of cardiac tissue engineering. Am. J. Physiol. Heart Circ. Physiol. 2012, 303:H133-H143. 10.1152/ajpheart.00007.2012.
48. Schaaf S., Eder A., Vollert I., Stöhr A., Hansen A., Eschenhagen T. Generation of strip-format fibrin-based engineered heart tissue (EHT). Card. Tissue Eng. Methods Mol. Biol. 2014, 121-129. 10.1007/978-1-4939-1047-2_11.
49. Hirt M.N., Sörensen N.A., Bartholdt L.M., Boeddinghaus J., Schaaf S., Eder A., et al. Increased afterload induces pathological cardiac hypertrophy: a new in vitro model. Basic Res. Cardiol. 2012, 107:307. 10.1007/s00395-012-0307-z.
50. Eder A., Hansen A., Uebeler J., Schulze T., Neuber C., Schaaf S., et al. Effects of proarrhythmic drugs on relaxation time and beating pattern in rat engineered heart tissue. Basic Res. Cardiol. 2014, 109. 10.1007/s00395-014-0436-7.
51. Hirt M.N., Hansen A., Eschenhagen T. Cardiac tissue engineering: state of the art. Circ. Res. 2014, 114:354-367. 10.1161/CIRCRESAHA.114.300522.
52. Vollert I., Schaaf S., Neuber C., Letuffe-Berniere D., Breckwoldt K., Shibamiya A., et al. Physiological and pharmacological characterization of human engineered heart tissue [Abstract]. Cardiovasc. Res. 2014, 7:143.
53. Hirt M.N., Werner T., Indenbirken D., Alawi M., Demin P., Kunze A., et al. Deciphering the microRNA signature of pathological cardiac hypertrophy by engineered heart tissue- and sequencing-technology. J. Mol. Cell. Cardiol. 2015, 81:1-9. 10.1016/j.yjmcc.2015.01.008.
54. Stöhr A., Friedrich F.W., Flenner F., Geertz B., Eder A., Schaaf S., et al. Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice. J. Mol. Cell. Cardiol. 2013, 10.1016/j.yjmcc.2013.07.011.
55. de Lange W.J., Hegge L.F., Grimes A.C., Tong C.W., Brost T.M., Moss R.L., et al. Neonatal mouse-derived engineered cardiac tissue: a novel model system for studying genetic heart disease. Circ. Res. 2011, 109:8-19. 10.1161/CIRCRESAHA.111.242354.
56. Mearini G., Stimpel D., Geertz B., Weinberger F., Krämer E., Schlossarek S., et al. Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice. Nat. Commun. 2014, 5:5515. 10.1038/ncomms6515.
57. Friedrich F.W., Wilding B.R., Reischmann S., Crocini C., Lang P., Charron P., et al. Evidence for FHL1 as a novel disease gene for isolated hypertrophic cardiomyopathy. Hum. Mol. Genet. 2012, 21:3237-3254. 10.1093/hmg/dds157.
58. Crocini C., Arimura T., Reischmann S., Eder A., Braren I., Hansen A., et al. Impact of ANKRD1 mutations associated with hypertrophic cardiomyopathy on contraction parameters of engineered heart tissue. Basic Res. Cardiol. 2013, 108. 10.1007/s00395-013-0349-x.
59. Chiron S., Tomczak C., Duperray A., Lainé J., Bonne G., Eder A., et al. Complex interactions between human myoblasts and the surrounding 3D fibrin-based matrix. PLoS One 2012, 7. 10.1371/journal.pone.0036173.
60. Juhas M., Engelmayr G.C., Fontanella A.N., Palmer G.M., Bursac N. Biomimetic engineered muscle with capacity for vascular integration and functional maturation in vivo. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:5508-5513. 10.1073/pnas.1402723111.
61. Nogawa H., Kawai T., Yajima M., Miura M., Ogawa T., Murakami K. Effects of probucol, a typical hERG expression inhibitor, on in vivo QT interval prolongation in conscious dogs. Eur. J. Pharmacol. 2013, 720:29-37. 10.1016/j.ejphar.2013.10.056.
62. Chen G., Gulbranson D.R., Hou Z., Bolin J.M., Ruotti V., Probasco M.D., et al. Chemically defined conditions for human iPSC derivation and culture. Nat. Methods 2011, 8:424-429. 10.1038/nmeth.1593.
63. Lian X., Zhang J., Azarin S.M., Zhu K., Hazeltine L.B., Bao X., et al. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/β-catenin signaling under fully defined conditions. Nat. Protoc. 2013, 8:162-175. 10.1038/nprot.2012.150.
64. Burridge P.W., Matsa E., Shukla P., Lin Z.C., Churko J.M., Ebert A.D., et al. Chemically defined generation of human cardiomyocytes. Nat. Methods 2014, 11:855-860. 10.1038/nmeth.2999.
65. Chong J.J.H., Yang X., Don C.W., Minami E., Liu Y.-W., Weyers J.J., et al. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature 2014, 510:273-277. 10.1038/nature13233.
66. Kempf H., Olmer R., Kropp C., Rückert M., Jara-Avaca M., Robles-Diaz D., et al. Controlling expansion and cardiomyogenic differentiation of human pluripotent stem cells in scalable suspension culture. Stem Cell Rep. 2014, 3:1132-1146. 10.1016/j.stemcr.2014.09.017.
67. Eschenhagen T., Zimmermann W.-H. Engineering myocardial tissue. Circ. Res. 2005, 97:1220-1231. 10.1161/01.RES.0000196562.73231.7d.
68. Naito H., Melnychenko I., Didié M., Schneiderbanger K., Schubert P., Rosenkranz S., et al. Optimizing engineered heart tissue for therapeutic applications as surrogate heart muscle. Circulation 2006, 114:I72-I178. 10.1161/CIRCULATIONAHA.105.001560.
69. Legant W.R., Pathak A., Yang M.T., Deshpande V.S., McMeeking R.M., Chen C.S. Microfabricated tissue gauges to measure and manipulate forces from 3D microtissues. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:10097-10102. 10.1073/pnas.0900174106.
70. Thavandiran N., Dubois N., Mikryukov A., Massé S., Simmons C.A., Deshpande V.S., Correction for Thavandiran, et al. Design and formulation of functional pluripotent stem cell-derived cardiac microtissues: table 1. Proc. Natl. Acad. Sci. 2014, 111:16973. 10.1073/pnas. 1420457111.
71. Tiburcy M., Didié M., Boy O., Christalla P., Döker S., Naito H., et al. Terminal differentiation, advanced organotypic maturation, and modeling of hypertrophic growth in engineered heart tissue. Circ. Res. 2011, 109:1105-1114. 10.1161/CIRCRESAHA.111.251843.
72. Hirt M.N., Boeddinghaus J., Mitchell A., Schaaf S., Börnchen C., Müller C., et al. Functional improvement and maturation of rat and human engineered heart tissue by chronic electrical stimulation. J. Mol. Cell. Cardiol. 2014, 74C:151-161. 10.1016/j.yjmcc.2014.05.009.
73. Shimizu T., Yamato M., Isoi Y., Akutsu T., Setomaru T., Abe K., et al. Fabrication of pulsatile cardiac tissue grafts using a novel 3-dimensional cell sheet manipulation technique and temperature-responsive cell culture surfaces. Circ. Res. 2002, 90:e40. 10.1161/hh0302.105722.
74. Bian W., Badie N., Himel H.D., Bursac N. Robust T-tubulation and maturation of cardiomyocytes using tissue-engineered epicardial mimetics. Biomaterials 2014, 35:3819-3828. 10.1016/j.biomaterials.2014.01.045.
75. Zacchigna S., Giacca M. Extra- and intracellular factors regulating cardiomyocyte proliferation in postnatal life. Cardiovasc. Res. 2014, 102:312-320. 10.1093/cvr/cvu057.
76. Zimmermann W.H., Fink C., Kralisch D., Remmers U., Weil J., Eschenhagen T. Three-dimensional engineered heart tissue from neonatal rat cardiac myocytes. Biotechnol. Bioeng. 2000, 68:106-114. 10.1002/(SICI)1097-0290(20000405)68.
77. Feldman M.D., Copelas L., Gwathmey J.K., Phillips P., Warren S.E., Schoen F.J., et al. Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation 1987, 75:331-339. 10.1161/01.CIR.75.2.331.
78. Schwinger R.H., Böhm M., Mittmann C., La Rosée K., Erdmann E. Evidence for a sustained effectiveness of sodium-channel activators in failing human myocardium. J. Mol. Cell. Cardiol. 1991, 23:461-471. 10.1016/0022-2828(91)90170-Q.
79. Nerbonne J.M., Kass R.S. Molecular physiology of cardiac repolarization. Physiol. Rev. 2005, 85:1205-1253. 10.1152/physrev.00002.2005.
80. Force T., Kolaja K.L. Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat. Rev. Drug Discov. 2011, 10:111-126. 10.1038/nrd3252.
81. Eschenhagen T., Mummery C., Knollmann B.C. Modelling sarcomeric cardiomyopathies in the dish: from human heart samples to iPSC cardiomyocytes 2015, Cardiovasc, Res. 10.1093/cvr/cvv017.
82. Moretti A., Bellin M., Welling A., Jung C.B., Lam J.T., Bott-Flügel L., et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N. Engl. J. Med. 2010, 363:1397-1409. 10.1056/NEJMoa0908679.
83. Itzhaki I., Maizels L., Huber I., Zwi-Dantsis L., Caspi O., Winterstern A., et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011, 471:225-229. 10.1038/nature09747.
84. Yazawa M., Hsueh B., Jia X., Pasca A., Bernstein J., Hallmayer J., et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 2011, 471:230-234. 10.1038/nature09855.
85. Fatima A., Xu G., Shao K., Papadopoulos S., Lehmann M., Arnáiz-Cot J.J., et al. In vitro modeling of ryanodine receptor 2 dysfunction using human induced pluripotent stem cells. Cell. Physiol. Biochem. 2011, 28:579-592. 10.1159/000335753.
86. Ma D., Wei H., Zhao Y., Lu J., Li G., Sahib N.B.E., et al. Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells. Int. J. Cardiol. 2013, 168:5277-5286. 10.1016/j.ijcard.2013.08.015.
87. Cho S.W., Kim S., Kim J.M., Kim J.-S. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat. Biotechnol. 2013, 31:230-232. 10.1038/nbt.2507.
88. Cong L., Ran F., Cox D., Lin S., Barretto R. Multiplex genome engineering using CRISPR/Cas systems. Science 2013, 339(80):819-823. 10.1038/nbt1319.
89. Radisic M., Park H., Shing H., Consi T., Schoen F.J., Langer R., et al. Functional assembly of engineered myocardium by electrical stimulation of cardiac myocytes cultured on scaffolds. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:18129-18134. 10.1073/pnas.0407817101.
90. Tandon N., Cannizzaro C., Chao P.P.-H.G., Maidhof R., Marsano A., Au H.T.H., et al. Electrical stimulation systems for cardiac tissue engineering. Nat. Protoc. 2009, 4:155-173. 10.1038/nprot.2008.183.Electrical.
91. Nunes S.S., Miklas J.W., Liu J., Aschar-Sobbi R., Xiao Y., Zhang B., et al. Biowire: a platform for maturation of human pluripotent stem cell-derived cardiomyocytes. Nat. Methods 2013, 10:781-787. 10.1038/nmeth.2524.
92. Yang X., Rodriguez M., Pabon L., Fischer K.A., Reinecke H., Regnier M., et al. Tri-iodo-l-thyronine promotes the maturation of human cardiomyocytes-derived from induced pluripotent stem cells. J. Mol. Cell. Cardiol. 2014, 72:296-304. 10.1016/j.yjmcc.2014.04.005.
93. + current in human induced pluripotent stem cell-derived cardiomyocytes. J. Mol. Cell. Cardiol. 2013, 60:36-46. 10.1016/j.yjmcc.2013.03.014.
94. Fatima A., Kaifeng S., Dittmann S., Xu G., Gupta M.K., Linke M., et al. The disease-specific phenotype in cardiomyocytes derived from induced pluripotent stem cells of two long qt syndrome type 3 patients. PLoS One 2013, 8:1-11. 10.1371/journal.pone.0083005.
95. Honda M., Kiyokawa J., Tabo M., Inoue T. Electrophysiological characterization of cardiomyocytes derived from human induced pluripotent stem cells. J. Pharmacol. Sci. 2011, 117:149-159. 10.1254/jphs.11038FP.
96. Lopez-Izquierdo A., Warren M., Riedel M., Cho S., Lai S., Lux R.L., et al. A near-infrared fluorescent voltage-sensitive dye allows for moderate-throughput electrophysiological analyses of human induced pluripotent stem cell-derived cardiomyocytes. AJP Hear. Circ. Physiol. 2014, 307:H1370-H1377. 10.1152/ajpheart.00344.2014.
97. Seki T., Yuasa S., Kusumoto D., Kunitomi A., Saito Y., Tohyama S., et al. Generation and characterization of functional cardiomyocytes derived from human T cell-derived induced pluripotent stem cells. PLoS One 2014, 9:e85645. 10.1371/journal.pone.0085645.
98. Matsa E., Rajamohan D., Dick E., Young L., Mellor I., Staniforth A., et al. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur. Heart J. 2011, 32:952-962. 10.1093/eurheartj/ehr073.
99. Tanaka T., Tohyama S., Murata M., Nomura F., Kaneko T., Chen H., et al. In vitro pharmacologic testing using human induced pluripotent stem cell-derived cardiomyocytes. Biochem. Biophys. Res. Commun. 2009, 385:497-502. 10.1016/j.bbrc.2009.05.073.
100. Jonsson M.K.B., Wang Q.-D., Becker B. Impedance-based detection of beating rhythm and proarrhythmic effects of compounds on stem cell-derived cardiomyocytes. Assay Drug Dev. Technol. 2011, 9:589-599. 10.1089/adt.2011.0396.
101. Zhang J., Wilson G.F., Soerens A.G., Koonce C.H., Yu J., Palecek S.P., et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ. Res. 2009, 104:e30-e41. 10.1161/CIRCRESAHA.108.192237.
102. Kensah G., Lara A.R., Dahlmann J., Zweigerdt R., Schwanke K., Hegermann J., et al. Murine and human pluripotent stem cell-derived cardiac bodies form contractile myocardial tissue in vitro. Eur. Heart J. 2013, 34:1134-1146. 10.1093/eurheartj/ehs349.
103. Chen G., Li S., Karakikes I., Ren L., Zi-Ying Chow M., Chopra A., et al. Phospholamban as a crucial determinant of the inotropic response of human pluripotent stem cell-derived ventricular cardiomyocytes and engineered 3-dimensional tissue constructs. Circ. Arrhythmia Electrophysiol. 2014, 8:193-202. 10.1161/CIRCEP.114.002049.
104. Zhang D., Shadrin I.Y., Lam J., Xian H.Q., Snodgrass H.R., Bursac N. Tissue-engineered cardiac patch for advanced functional maturation of human ESC-derived cardiomyocytes. Biomaterials 2013, 34:5813-5820. 10.1016/j.biomaterials.2013.04.026.
105. Heijman J., Dobrev D. Rat engineered heart tissue: a novel tool in the safety pharmacology toolkit?. Basic Res. Cardiol. 2014, 109. 10.1007/s00395-014-0437-6.